Research programme: small-molecule antivirals - Kemin Pharma/USAMRIID

Drug Profile

Research programme: small-molecule antivirals - Kemin Pharma/USAMRIID

Alternative Names: KPE00001175

Latest Information Update: 23 Sep 2008

Price : $50

At a glance

  • Originator Kemin Pharma
  • Developer United States Army Medical Research Institute of Infectious Diseases
  • Class Carbohydrates; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Coronavirus infections; Smallpox

Most Recent Events

  • 23 Sep 2008 Discontinued - Preclinical for Smallpox in Belgium (unspecified route)
  • 23 Sep 2008 Discontinued - Preclinical for Smallpox in USA (unspecified route)
  • 23 Sep 2008 Discontinued - Preclinical for Coronavirus infections in Belgium (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top